Overview
- Intuitive quietly extended reuse limits for several tools, notably boosting five force‑feedback instruments from six uses to 15 uses and planning longer lives for older standard instruments to ease supply constraints.
- The company's shares have fallen sharply this year as investors worry the changes will reduce recurring instruments and accessories revenue that Intuitive earns each time a tool is used.
- Intuitive reported strong first‑quarter results with revenue of $2.77 billion, instruments and accessories revenue of $1.69 billion (both up 23% year over year), and EPS of $2.28.
- Wall Street is divided: several firms downgraded the stock after the Q1 report while Goldman Sachs raised its price target to $558 and argued the force‑feedback change has no per‑procedure revenue impact.
- Markets are waiting for Intuitive's July earnings call for company‑modeled guidance on the revenue effect, which will also clarify how lower per‑procedure costs could affect hospital budgets, adoption of the tools, and opportunities for refurbishers.